Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gentamicin + polymyxin + probiotics
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital, Zhejiang University School of Medicine
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Gentamicin + polymyxin + probiotics is a combination therapeutic regimen designed for the selective digestive decolonization (SDD) of carbapenem-resistant Enterobacteriaceae (CRE). Developed by the First Affiliated Hospital, Zhejiang University School of Medicine, the regimen typically involves the oral administration of gentamicin and a polymyxin (such as polymyxin E/colistin) to eliminate resistant Gram-negative bacteria from the intestinal reservoir. Gentamicin acts by binding to the bacterial 30S ribosomal subunit to inhibit protein synthesis, while polymyxins disrupt the bacterial outer membrane by binding to lipopolysaccharides (LPS). The inclusion of probiotics is intended to mitigate the disruption of the normal gut microbiota caused by the antibiotics, promoting the restoration of a healthy microbial environment and preventing the recurrence of CRE colonization.
- Other names
- gentamicin + polymyxin E + probioticsGPP regimenoral gentamicin and polymyxin with probiotics
02
Targets
Bacterial Ribosome
Beyond the preview
Go deeper on gentamicin + polymyxin + probiotics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gentamicin + polymyxin + probiotics.